1Arnett FC,Edworthy SM, Bloch DA, et al. The American Rh-eumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum,1988,31(3) :315 - 324.
3Wolfe F, Rehman Q, Lane N, et al. Starling a disease modifying Antirheumatic drug or a biologic agen in rheumatoid arthritis:standards of practice for RA treatment [ J ]. J Rheumatol, 2001,28 (7) : 1704 - 1711.
4Kippel John H, Crofford Leslie J. Primer on the Rheumatic disease [ M]. Georgia: Arthritis Foundation, 2001 : 209 - 232.
7Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug mono- therapyin rheumatoid arthritis. Ann Rheum Dis, 2013, 72(12): 1897-1904.
8Cutolo M, Meroni M. Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis. J Inflamm Res, 2013, 6:129-137.
9Kim JW, ChoiI A, Lee E, et al. Tofacitinib prevents radiographic progression in rheumatoid arthritis. J Korean Med Sci, 2013, 28(8): 1134- I 138.
10American Collage of Rheumatology Subcommittee on Rheumatoid At-thrifts Guidelines. Guidelines for the management of rheumatoid atthritis (2002 update). Arthritis Rheum, 2002, 46(2): 328-3416.
